Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
T

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achieve CR, MRD- Patients Have Better Survival, Many MRD Related Specifics Need to Be Defined

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Thomas Martin
November 18, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Emory Global Perioperative Health Alliance

Emory Global Perioperative Alliance virtual Symposium: "Interprofessional …

Sat, Mar 6, 2021
The O'Neal Comprehensive Cancer Center at UAB

UAB Hematology Review 2021

Fri, Mar 5, 2021
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therapy …

Feat. A. Rosko
14:16
2nd SOHO Italian Conference

2020 SOHO Update on MM: What Is the Role of Transplant and MRD? How Do Tri…

Feat. K. Anderson
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Multiple Myeloma: Smoldering MM, Ind…

Feat. K. Shain
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy and R…

16:22
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Newly Diagnosed MM: Can VMP Combination Improve PFS/O…

Feat. P. Voorhees
14:57
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on HDT in Frontline MM: Is Lenalidomide, Bortezomib, …

Feat. A. Nooka
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Sequen…

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
15:22
SOHO Italy 1st School of Multiple Myeloma

Dissecting Daratumumab Mechanisms of Resistance in MM: Identification of N…

Feat. M. Claudio Da Via
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the My…

Feat. J. Berdeja
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

08:40
Surbhi Sidana

Duration of Complete Response Impacts Overall Survival in Multiple Myeloma

09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Myelo…

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
16:06
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Smoldering MM: Why Should We Not Treat It Early?

Feat. A. Dispenzieri